150 related articles for article (PubMed ID: 27121864)
1. Proof of concept for inhibiting metastasis: circulating tumor cell-triggered localized release of anticancer agent via a structure-switching aptamer.
Chen N; Yang X; Wang Q; Jian L; Shi H; Qin S; Wang K; Huang J; Liu W
Chem Commun (Camb); 2016 May; 52(41):6789-92. PubMed ID: 27121864
[TBL] [Abstract][Full Text] [Related]
2. Aptamer/Graphene Quantum Dots Nanocomposite Capped Fluorescent Mesoporous Silica Nanoparticles for Intracellular Drug Delivery and Real-Time Monitoring of Drug Release.
Zheng FF; Zhang PH; Xi Y; Chen JJ; Li LL; Zhu JJ
Anal Chem; 2015 Dec; 87(23):11739-45. PubMed ID: 26524192
[TBL] [Abstract][Full Text] [Related]
3. Photo-controlled delivery of a potent analogue of doxorubicin.
Dupart PS; Mitra K; Lyons CE; Hartman MCT
Chem Commun (Camb); 2019 May; 55(39):5607-5610. PubMed ID: 31021353
[TBL] [Abstract][Full Text] [Related]
4. Combination of Doxorubicin with Gemcitabine-Incorporated G-Quadruplex Aptamer Showed Synergistic and Selective Anticancer Effect in Breast Cancer Cells.
Joshi M; Choi JS; Park JW; Doh KO
J Microbiol Biotechnol; 2019 Nov; 29(11):1799-1805. PubMed ID: 31546295
[TBL] [Abstract][Full Text] [Related]
5. Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro.
Alibolandi M; Ramezani M; Sadeghi F; Abnous K; Hadizadeh F
Int J Pharm; 2015 Feb; 479(1):241-51. PubMed ID: 25529433
[TBL] [Abstract][Full Text] [Related]
6. Aptamer-drug conjugation for targeted tumor cell therapy.
Donovan MJ; Meng L; Chen T; Zhang Y; Sefah K; Tan W
Methods Mol Biol; 2011; 764():141-52. PubMed ID: 21748638
[TBL] [Abstract][Full Text] [Related]
7. Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy.
Luo YL; Shiao YS; Huang YF
ACS Nano; 2011 Oct; 5(10):7796-804. PubMed ID: 21942498
[TBL] [Abstract][Full Text] [Related]
8. Aptamer CaCO3 nanostructures: a facile, pH-responsive, specific platform for targeted anticancer theranostics.
Zhou C; Chen T; Wu C; Zhu G; Qiu L; Cui C; Hou W; Tan W
Chem Asian J; 2015 Jan; 10(1):166-71. PubMed ID: 25377905
[TBL] [Abstract][Full Text] [Related]
9. Microenvironmental Control of MUC1 Aptamer-Guided Acid-Labile Nanoconjugate within Injectable Microporous Hydrogels.
Xu C; Han X; Jiang Y; Yuan S; Wu Z; Wu Z; Qi X
Bioconjug Chem; 2017 Oct; 28(10):2530-2537. PubMed ID: 28949511
[TBL] [Abstract][Full Text] [Related]
10. Biodegradable ZnO@polymer core-shell nanocarriers: pH-triggered release of doxorubicin in vitro.
Zhang ZY; Xu YD; Ma YY; Qiu LL; Wang Y; Kong JL; Xiong HM
Angew Chem Int Ed Engl; 2013 Apr; 52(15):4127-31. PubMed ID: 23463695
[No Abstract] [Full Text] [Related]
11. Boron Nitride Nanoparticles with a Petal-Like Surface as Anticancer Drug-Delivery Systems.
Sukhorukova IV; Zhitnyak IY; Kovalskii AM; Matveev AT; Lebedev OI; Li X; Gloushankova NA; Golberg D; Shtansky DV
ACS Appl Mater Interfaces; 2015 Aug; 7(31):17217-25. PubMed ID: 26192448
[TBL] [Abstract][Full Text] [Related]
12. An in vitro assessment of novel chitosan/bimetallic PtAu nanocomposites as delivery vehicles for doxorubicin.
Maney V; Singh M
Nanomedicine (Lond); 2017 Nov; 12(21):2625-2640. PubMed ID: 28965478
[TBL] [Abstract][Full Text] [Related]
13. Anticancer nano-prodrugs with drug release triggered by intracellular dissolution and hydrogen peroxide response.
Shibata A; Koseki Y; Tanita K; Kitajima S; Oka K; Maruoka K; Suzuki R; Thi Ngoc Dao A; Kasai H
Chem Commun (Camb); 2024 Jun; 60(50):6427-6430. PubMed ID: 38829169
[TBL] [Abstract][Full Text] [Related]
14. Dual Stimuli-Responsive Controlled Release Nanocarrier for Multidrug Resistance Cancer Therapy.
Jiao X; Wang Z; Wang F; Wen Y
Chemphyschem; 2019 Dec; 20(24):3271-3275. PubMed ID: 31654459
[TBL] [Abstract][Full Text] [Related]
15. An NIR-triggered and thermally responsive drug delivery platform through DNA/copper sulfide gates.
Zhang L; Li Y; Jin Z; Yu JC; Chan KM
Nanoscale; 2015 Aug; 7(29):12614-24. PubMed ID: 26147639
[TBL] [Abstract][Full Text] [Related]
16. High expression of MnSOD promotes survival of circulating breast cancer cells and increases their resistance to doxorubicin.
Fu A; Ma S; Wei N; Tan BX; Tan EY; Luo KQ
Oncotarget; 2016 Aug; 7(31):50239-50257. PubMed ID: 27384484
[TBL] [Abstract][Full Text] [Related]
17. Carboxylated hydroxyethyl starch: a novel polysaccharide for the delivery of doxorubicin.
Paleos CM; Sideratou Z; Theodossiou TA; Tsiourvas D
Chem Biol Drug Des; 2015 May; 85(5):653-8. PubMed ID: 25303215
[TBL] [Abstract][Full Text] [Related]
18. A polyvalent aptamer system for targeted drug delivery.
Zhang Z; Ali MM; Eckert MA; Kang DK; Chen YY; Sender LS; Fruman DA; Zhao W
Biomaterials; 2013 Dec; 34(37):9728-35. PubMed ID: 24044994
[TBL] [Abstract][Full Text] [Related]
19. Aptamer-based liposomes improve specific drug loading and release.
Plourde K; Derbali RM; Desrosiers A; Dubath C; Vallée-Bélisle A; Leblond J
J Control Release; 2017 Apr; 251():82-91. PubMed ID: 28238787
[TBL] [Abstract][Full Text] [Related]
20. The effect of molecular structure on the anticancer drug release rate from prodrug nanoparticles.
Ikuta Y; Koseki Y; Onodera T; Oikawa H; Kasai H
Chem Commun (Camb); 2015 Aug; 51(64):12835-8. PubMed ID: 26165183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
